OncLive TV

Ferdinandos Skoulidis, MD, PhD, MRCP, discusses the results of subgroup analysis from the phase 2 CodeBreaK 100 trial in patients with KRAS G12C-mutant non–small cell lung cancer.

Martin Reck, MD, PhD, discusses updated results of the phase 3 CheckMate 9LA study in advanced non–small cell lung cancer.

Toni K. Choueiri, MD, discusses the efficacy of pembrolizumab as a post-nephrectomy adjuvant therapy for patients with renal cell carcinoma from the phase 3 KEYNOTE-564 trial.

Sameem Abedin, MD, discusses the need for risk stratification prior to giving chemoimmunotherapy to patients with chronic lymphocytic leukemia.

Charles Powell, MD, MBA, discusses remaining questions with interstitial lung disease in HER2-positive breast cancer.

Bijal Shah, MD, MS, discusses shortcomings with BTK inhibitors in high-risk mantle cell lymphoma.

Faith Davies, MD, discusses key considerations for developing a treatment strategy for patients with early-relapse multiple myeloma.

Earle Burgess, MD, discusses the need for improved biomarkers for PARP inhibitors in prostate cancer.

Rogerio C. Lilenbaum, MD, discusses the clinical implications of the FDA approval of lurbinectedin in metastatic small cell lung cancer.

Hans Hammers, MD, PhD, discusses the potential utility of HIF-2α inhibitors in renal cell carcinoma.

Elyse Lower, MD, discusses the importance of tucatinib in the treatment of patients with HER2-positive breast cancer.

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Helen J. Ross, MD, discusses toxicity concerns with combinations therapies in EGFR-mutant non–small cell lung cancer.

Monalisa Ghosh, MD, discusses the role of idecabtagene vicleucel in relapsed/refractory multiple myeloma landscape.

Milind Javle, MD, discusses the FDA approval of infigratinib in FGFR-mutated cholangiocarcinoma.

Gareth J. Morgan, MD, PhD, discusses optimizing treatments for patients with ultra high–risk multiple myeloma.

Mark A. Socinski, MD, discusses the utility of circulating tumor DNA testing in lung cancer.

James H. Doroshow, MD, discusses strategies that were implemented to increase patient accrual to clinical trials during the COVID-19 pandemic.

Álvaro Juárez Soto, MD, discusses the rationale to analyze the Latin American subgroup of patients with metastatic hormone-sensitive prostate cancer evaluated in the phase 3 TITAN trial.

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

James A. DeCaprio, MD, discusses raising awareness in Merkel cell carcinoma.

Sandra P. D’Angelo, MD, discusses the incidence and prognosis of patients with Merkel cell carcinoma.

Jing-Yi Chern, MD, ScM, discusses future research directions in the treatment of patients with ovarian cancer.

Joshua Strauss, MD, discusses future research directions for the treatment of patients with small cell lung cancer.

Stephanie J. Lee, MD, MPH, discusses the results of the phase 3 REACH3 trial in chronic graft-vs-host disease.

Thomas Hutson, DO, PharmD, discusses key safety considerations with cabozantinib in patients with metastatic renal cell carcinoma.

Vineet Talwar, DM, FRCP, DNB, FICP, FIMSA, MNAMS, discusses the utility of immunotherapy in metastatic urothelial carcinoma.

Charles Powell, MD, MBA, discusses managing fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.